How fast does semaglutide work?

Appetite changes often appear within the first week or two, but meaningful weight loss builds over months as you reach the maintenance dose. Most trial weight loss accrues over the first 6–9 months.

What happens if I stop?

Studies show most people regain a large share of lost weight within a year of stopping, because the underlying appetite drivers return. GLP-1 therapy is generally treated as long-term, not a short course.

FDA-approved

Semaglutide

GLP-1 receptor agonist · Injection or oral · Sold as Ozempic, Wegovy, Rybelsus

The most widely prescribed GLP-1 — sold as Wegovy for weight loss, Ozempic for type 2 diabetes, and Rybelsus as a daily pill.

Last reviewed 2026-09-01 by the TopGLP1 Editorial Team

Educational, not medical advice. This page explains GLP-1 medications in general terms. Only a licensed clinician who knows your history can decide what's right for you.

Key takeaways

One molecule, three brands: Wegovy (weight loss), Ozempic (diabetes), Rybelsus (oral diabetes).
Once-weekly injection; average ~15% body-weight reduction over 68 weeks in the STEP trials.
Dose is escalated slowly over 16+ weeks to limit nausea.
Widely available as a lower-cost compounded version through telehealth.

Semaglutide is a once-weekly GLP-1 receptor agonist and the medication most people mean when they say “the weight-loss shot.” The same molecule is marketed under three brand names: Wegovy (approved for chronic weight management), Ozempic (approved for type 2 diabetes), and Rybelsus (a daily oral tablet for type 2 diabetes).

In its landmark weight-management trial, adults without diabetes lost on average roughly 15% of their starting body weight over 68 weeks alongside diet and activity changes — a result that moved GLP-1 medications from the diabetes clinic into mainstream obesity care.

Because branded supply has been tight and expensive, semaglutide is also the molecule most commonly dispensed as a compounded preparation through telehealth clinics, which is why pricing and legality vary so much depending on how you access it.

How semaglutide works

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. Semaglutide is a long-acting mimic of that hormone. It binds the same receptors, but instead of breaking down in minutes it stays active for about a week.

Three effects drive weight loss: it slows how quickly the stomach empties (so you feel full longer), it acts on appetite centers in the brain to reduce hunger and food “noise,” and it prompts the pancreas to release insulin only when blood sugar is high — which is why the same drug also lowers glucose in diabetes.

The net result for most people is smaller portions, fewer cravings, and less preoccupation with food, without the jittery stimulant feeling of older appetite suppressants.

How well it works

~15% average body-weight loss at 68 weeks (STEP 1).

In the STEP program of randomized trials, adults with overweight or obesity but without diabetes lost an average of about 15% of body weight on 2.4 mg weekly semaglutide, versus ~2.4% on placebo. People with type 2 diabetes tend to lose somewhat less. Results depend heavily on reaching and staying on the maintenance dose.

STEP 1 (no diabetes)~14.9% mean weight loss vs 2.4% placebo over 68 weeks

STEP 2 (type 2 diabetes)~9.6% mean weight loss on 2.4 mg

SELECT (cardiovascular)20% reduction in major cardiovascular events in adults with existing heart disease

Dosing schedule

Wegovy uses a fixed 16-week escalation to the maintenance dose. Doses are stepped up slowly so your gut adapts — rushing the schedule is the main cause of severe nausea.

Weeks 1–40.25 mg once weekly

Starter dose — not meant to cause much weight loss yet.

Weeks 5–80.5 mg once weekly

Weeks 9–121.0 mg once weekly

Weeks 13–161.7 mg once weekly

Week 17+2.4 mg once weekly

Maintenance dose for weight management.

Ozempic (diabetes) tops out lower, typically at 1.0–2.0 mg weekly.
Rybelsus is a daily tablet (7 mg or 14 mg) taken on an empty stomach with a small sip of water, then nothing by mouth for 30 minutes.
If a dose causes intolerable side effects, clinicians often hold you at the current step longer rather than pushing up.

Side effects & safety

Common

• Nausea (most common, usually worst in the first weeks and after each dose increase)
• Constipation or diarrhea
• Vomiting and burping
• Reduced appetite and early fullness
• Fatigue during escalation

Serious (uncommon)

• Pancreatitis (severe, persistent abdominal pain — stop and seek care)
• Gallbladder problems, especially with rapid weight loss
• Boxed warning for thyroid C-cell tumors seen in rodents; avoid with a personal/family history of medullary thyroid carcinoma or MEN 2
• Dehydration from vomiting/diarrhea, which can affect the kidneys

Most GI side effects fade as your body adapts. Eating smaller, lower-fat meals, stopping when full, and staying hydrated help. Persistent severe abdominal pain, signs of an allergic reaction, or vision changes warrant prompt medical attention.

What it costs

Branded (cash): $1,000–$1,350/month list price for Wegovy without insurance (manufacturer cash programs can lower this)
Compounded (telehealth): $150–$300/month typical through telehealth (availability varies with FDA shortage status)
Insurance: Coverage for weight loss specifically is inconsistent — many plans cover Ozempic for diabetes but exclude Wegovy for obesity. Prior authorization is common.

Who it's for — and who should avoid it

Often a good fit

Adults with a BMI ≥ 30, or ≥ 27 with a weight-related condition
People who want a well-studied, once-weekly option with the longest track record
People with type 2 diabetes (as Ozempic/Rybelsus)

Not recommended for

Anyone with a history of medullary thyroid carcinoma or MEN 2
People with a history of pancreatitis (use caution, discuss with a clinician)
People who are pregnant or trying to conceive

Common questions

Chemically, yes — both are semaglutide. They differ in approved use and maximum dose: Wegovy is approved and dosed for weight management (up to 2.4 mg), while Ozempic is approved for type 2 diabetes (up to 2.0 mg).